Symposium: Psychedelic Therapy for Substance Use Disorders: Neurobiology, Evidence Base, Regulatory Considerations, and Unintended Consequences-Psychedelic Therapy for Substance Use Disorders: Neurobiology, Evidence Base, Regulatory Considerations, and Unintended Consequences

Psychedelic Therapy for Substance Use Disorders: Neurobiology, Evidence Base, Regulatory Considerations, and Unintended Consequences

Back to course

Video Transcription

Video Summary

The video delves extensively into the exploration of psychedelic therapy, particularly focusing on its application for treating substance use disorders. Dr. Steve Ross, a renowned expert from NYU, explains the history and current resurgence of interest in psychedelics such as LSD and psilocybin. He discusses the potential cognitive dissonance in using these substances, typically considered drugs of abuse, as therapeutic agents. Dr. Ross highlights the complex legal and societal backgrounds of psychedelics, emphasizing the importance of embracing a rational and evidence-based understanding.<br /><br />He narrates the fascinating journey of LSD from being a psychiatric wonder drug to a demonized substance and describes the unique therapeutic potential these psychoactive substances hold. Clinical trials suggest promising results, particularly in addressing alcohol use disorder, with reductions in heavy drinking reported among participants. However, these findings are preliminary and necessitate further rigorous research.<br /><br />Meanwhile, Dr. Bertha Madras focuses on the neurobiological mechanisms underpinning psychedelics' effects, stressing the imperative of understanding the long-term implications and unintended consequences of these therapies. Lastly, Jack Henningfield discusses regulatory paths and challenges, advocating for careful FDA oversight to ensure psychedelics' safe and equitable therapeutic use. Both speakers underscore the necessity for more research to clarify psychedelics' efficacy, mechanisms, and safety as we navigate this renewed wave of interest in psychedelic medicine.

Asset Caption

Please note: The slide deck from this presentation is unavailable for distribution.

Keywords

psychedelic therapy

substance use disorders

Dr. Steve Ross

NYU

LSD

psilocybin

cognitive dissonance

therapeutic agents

legal and societal backgrounds

evidence-based understanding

alcohol use disorder

clinical trials

Dr. Bertha Madras

neurobiological mechanisms

FDA oversight

	The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.		400 Massasoit Avenue Suite 108 East Providence, RI 02914 cmecpd@aaap.org Privacy	About Advocacy Membership Fellowship Education and Resources Training Events